Overview
- Topline LUCIDITY results reported Tuesday showed avexitide reduced level 2 and level 3 hypoglycemic events by 55% versus placebo in a 16‑week, randomized, double‑blind trial of 78 Roux‑en‑Y patients with a highly significant p‑value of 0.000003.
- Avexitide blocks GLP‑1 receptors on pancreatic beta cells to blunt excess insulin release after meals, targeting an unmet need because there are no FDA‑approved treatments for post‑bariatric hypoglycemia.
- The drug was generally well tolerated in the trial with mostly mild‑to‑moderate side effects such as diarrhea and injection‑site bruising or erythema, and the company reported no serious adverse events.
- Amylyx said it will prepare a New Drug Application for submission by the end of 2026 and has launched a $350 million underwritten stock offering to finance pre‑commercial activities and manufacturing capacity.
- The readout sent Amylyx shares sharply higher, prompted analyst upgrades and wide peak‑sales forecasts, and the company is continuing a 32‑week open‑label extension while preparing detailed safety and CGM data for upcoming medical meetings.